Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 149

Similar articles for PubMed (Select 18480007)

1.

HER-2/neu assessment in breast cancer using the original FDA and new ASCO/CAP guideline recommendations: impact on selecting patients for herceptin therapy.

Brunelli M, Manfrin E, Martignoni G, Bersani S, Remo A, Reghellin D, Chilosi M, Bonetti F.

Am J Clin Pathol. 2008 Jun;129(6):907-11. doi: 10.1309/MD79CDXN1D01E862.

2.

In the news: From ASCO 2015.

Hutchinson L.

Nat Rev Clin Oncol. 2015 Jun 23. doi: 10.1038/nrclinonc.2015.109. [Epub ahead of print] No abstract available.

PMID:
26099981
3.

AACR, ASCO issue statement on E-cigarette regulation.

Printz C.

Cancer. 2015 Jun 1;121(11):1723. doi: 10.1002/cncr.29448. No abstract available.

PMID:
25994528
4.

Comparison of the 2007 and 2013 ASCO/CAP evaluation systems for HER2 amplification in breast cancer.

Pu X, Shi J, Li Z, Feng A, Ye Q.

Pathol Res Pract. 2015 Jun;211(6):421-5. doi: 10.1016/j.prp.2014.09.010. Epub 2014 Nov 7.

5.

2013 ASCO/CAP updated guidelines for human epidermal growth factor receptor 2 testing: Impact on routine practice.

Pennacchia I, Carbone A, Di Cerbo A, Vecchio FM, Arena V.

Breast. 2015 Jun;24(3):285-6. doi: 10.1016/j.breast.2015.01.014. Epub 2015 Feb 20.

PMID:
25704981
6.

[2014 update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France].

Penault-Llorca F, Vincent-Salomon A, MacGrogan G, Roger P, Treilleux I, Valent A, Mathieu MC, Antoine M, Becette V, Bor C, Brabencova E, Charafe-Jauffret E, Chenard MP, Dauplat MM, Delrée P, Devouassoux M, Fiche M, Fondrevelle ME, Fridman V, Garbar C, Genin P, Ghnassia JP, Haudebourg J, Laberge-Le Couteulx S, Loussouarn D, Maran-Gonzalez A, Marcy M, Michenet P, Poulet B, Sagan C, Trassard M, Verriele V, Arnould L, Lacroix-Triki M; GEFPICS.

Ann Pathol. 2014 Oct;34(5):352-65. doi: 10.1016/j.annpat.2014.08.018. Epub 2014 Sep 26. French.

PMID:
25439988
7.

Selecting and Pre-setting Amplification for Children: Where Do We Begin?

Lewis DE.

Trends Amplif. 1999 Jun;4(2):72-89. doi: 10.1177/108471389900400207. No abstract available.

8.

Gene status in HER2 equivocal breast carcinomas: impact of distinct recommendations and contribution of a polymerase chain reaction-based method.

Sapino A, Maletta F, Verdun di Cantogno L, Macrì L, Botta C, Gugliotta P, Scalzo MS, Annaratone L, Balmativola D, Pietribiasi F, Bernardi P, Arisio R, Viberti L, Guzzetti S, Orlassino R, Ercolani C, Mottolese M, Viale G, Marchiò C.

Oncologist. 2014 Nov;19(11):1118-26. doi: 10.1634/theoncologist.2014-0195. Epub 2014 Oct 16.

PMID:
25323485
9.

ASCO Reports: Highlights from Exclusive Oncology Interviews.

[No authors listed]

Oncology (Williston Park). 2012 Jul 9;26(7). pii: 168375. No abstract available.

10.

Clinicopathological variables predicting HER-2 gene status in immunohistochemistry-equivocal (2+) invasive breast cancer.

Ji Y, Sheng L, Du X, Qiu G, Chen B, Wang X.

J Thorac Dis. 2014 Jul;6(7):896-904. doi: 10.3978/j.issn.2072-1439.2014.07.27.

11.

Laboratory compliance with the American Society of Clinical Oncology/College of American Pathologists human epidermal growth factor receptor 2 testing guidelines: a 3-year comparison of validation procedures.

Dyhdalo KS, Fitzgibbons PL, Goldsmith JD, Souers RJ, Nakhleh RE.

Arch Pathol Lab Med. 2014 Jul;138(7):876-84. doi: 10.5858/arpa.2013-0731-CP.

PMID:
24978913
12.

Overexpression of the HER2/neu Gene: A New Therapeutic Possibility for Patients With Advanced Gallbladder Cancer.

Roa I, de Toro G, Schalper K, de Aretxabala X, Churi C, Javle M.

Gastrointest Cancer Res. 2014 Mar;7(2):42-8.

13.

Interobserver variability in HER-2/neu reporting on immunohistochemistry in breast carcinomas.

Mamoon N, Syed FN, Mushtaq S, Nasir H, Ahmad IN.

J Pak Med Assoc. 2014 Feb;64(2):151-4.

PMID:
24640802
14.

[HER2 testing in breast cancer: rereading the ASCO/CAP guideline].

Wang W, Xiang JJ, Cui HD, Liu J, Xu RJ.

Zhonghua Wai Ke Za Zhi. 2013 Oct;51(10):875-8. Chinese. No abstract available.

PMID:
24433762
15.

The updated ASCO/CAP guideline recommendations for HER2 testing in the management of invasive breast cancer: a critical review of their implications for routine practice.

Rakha EA, Starczynski J, Lee AH, Ellis IO.

Histopathology. 2014 Apr;64(5):609-15. doi: 10.1111/his.12357. Epub 2014 Jan 31. Review.

PMID:
24382093
16.

Breast cancer: updated guideline recommendations for HER2 testing.

Rakha EA, Ellis IO.

Nat Rev Clin Oncol. 2014 Jan;11(1):8-9. doi: 10.1038/nrclinonc.2013.230. Epub 2013 Dec 10.

PMID:
24322598
17.
18.

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF; American Society of Clinical Oncology; College of American Pathologists.

Arch Pathol Lab Med. 2014 Feb;138(2):241-56. doi: 10.5858/arpa.2013-0953-SA. Epub 2013 Oct 7.

19.

HER2 testing: current status and future directions.

Perez EA, Cortés J, Gonzalez-Angulo AM, Bartlett JM.

Cancer Treat Rev. 2014 Mar;40(2):276-84. doi: 10.1016/j.ctrv.2013.09.001. Epub 2013 Sep 11. Review.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk